Hemrajani Rekha 4

Accession 0001193125-26-018021

CIK 0001810182other

View on SEC.gov Company Profile

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 4:30 PM ET

Size

5.1 KB

Accession

0001193125-26-018021

Research Summary

AI-generated summary of this filing

Updated Jan 22, 2026

ALX Oncology Director Rekha Hemrajani Receives 40,400-Share Award

What Happened
Rekha Hemrajani, a director of ALX Oncology Holdings, Inc. (ALXO), received a grant of 40,400 derivative shares on January 20, 2026. The grant is reported at $0.00 per share (no cash paid at grant). This was an award/derivative grant (transaction code A), not an open-market purchase or sale.

Key Details

Transaction date: January 20, 2026; Form 4 filed January 21, 2026 (timely).
Instrument: Derivative award (reported as A) — 40,400 shares at $0.00.
Vesting: Shares subject to the option vest in 12 equal monthly installments beginning February 20, 2026 (footnote).
Shares owned after transaction: not specified in the filing.
No sale or cash exercise occurred; this is a compensation/award grant, not a 10b5-1 trade or gift.

Context
This is a typical compensation award to an insider and is not an immediate market purchase or sale. Because vesting occurs monthly over the next year, the full grant will only convert to owned shares as portions vest; unvested portions may be forfeitable. Such awards are common for retention/compensation and should be viewed differently from outright purchases (which may signal buy-side conviction) or sales (which may signal liquidity-taking).